BC Innovations | Sep 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...
BC Week In Review | Jul 14, 2014
Company News

Wilex, RedHill deal

Wilex granted RedHill exclusive rights to develop and commercialize Mesupron outside of Taiwan and China, including Hong Kong and Macau. Wilex will receive $1 million up front and is eligible for tiered royalties from the...
BC Week In Review | Apr 7, 2014
Company News

Link Health, Wilex deal

Wilex granted Link Health exclusive rights to develop and commercialize Mesupron in Taiwan and China, including Hong Kong and Macau, for all cancer indications. Wilex is eligible for an upfront payment and milestones totaling more...
BC Week In Review | Feb 3, 2014
Company News

Wilex cancer news

Wilex will reduce headcount by 41 (80%) to 10 at its headquarters in Munich. The company said it would discontinue clinical development "stepwise" but declined to provide details on specific early stage programs. Wilex will...
BioCentury | Mar 11, 2013
Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc. 's BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its rationale...
BC Week In Review | Oct 22, 2012
Clinical News

Girentuximab: Phase III data

Wilex said an independent DMC has recommended terminating the double-blind, international Phase III ARISER trial in 864 clear cell RCC patients after IV Rencarex missed the trial's primary endpoint of improving median DFS vs. placebo....
BC Extra | Oct 17, 2012
Top Story

Wilex plummets on Rencarex miss

Wilex AG (Xetra:WL6) fell EUR 2.40 (62%) to EUR 1.50 on Tuesday after Rencarex girentuximab missed the primary endpoint of improving median disease-free survival (DFS) vs. placebo in the Phase III ARISER trial to treat...
BC Week In Review | Jun 18, 2012
Clinical News

Mesupron: Phase II data

A double-blind, international Phase II trial in 132 patients with HER2-negative metastatic breast cancer showed that first-line treatment with once-daily oral 200 mg Mesupron plus twice-daily Xeloda capecitabine led to a median PFS, the primary...
BioCentury | Jun 18, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Arena Pharmaceuticals Inc. (NASDAQ:ARNA) gained $1.78 (27%) to $8.40 last week ahead of a June 27 PDUFA date for an NDA for lorcaserin to treat obesity. BTG plc (LSE:BTG) was off 1.80p to...
BC Extra | Jun 15, 2012
Clinical News

Wilex reports PFS data for Mesupron in breast cancer

Wilex AG (Xetra:WL6) said first-line treatment with once-daily oral Mesupron plus twice-daily capecitabine led to a median progression-free survival, the primary endpoint, of 8.3 months vs. 7.5 months for capecitabine alone in a Phase II...
Items per page:
1 - 10 of 37